Michelle McMurry-Heath washed overboard at BIO as industry group wrestles over its future, hunts new CEO
In the end, the internal tensions ripping at BIO had barely surfaced in fresh turmoil then the stormy surface waters were smoothed by CEO Michelle McMurry-Heath’s quick exit. Late Monday came word that she had resigned from her top post, swapping it for an advisory position, and soon after we learned that longtime biotech exec Rachel King would be taking her position until they can find a full-time replacement.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.